E-Cadherin Expression in Libyan Patients with Colorectal Carcinoma
[1]
Raja Aljafil , Department of Pathology, Faculty of Medicine, Benghazi University, Benghazi, Libya.
[2]
Fatma Emaetig , Department of Pathology, Faculty of Medicine, Benghazi University, Benghazi, Libya.
[3]
Salha Sassi , Department of Pathology, Faculty of Medicine, Benghazi University, Benghazi, Libya.
[4]
Ibtesam El Hasad , Department of Pathology, Faculty of Medicine, Benghazi University, Benghazi, Libya.
[5]
Khaled El Gehani , Department of Pathology, Faculty of Medicine, Benghazi University, Benghazi, Libya.
[6]
Omran El-Fituri , Department of Pathology, Faculty of Medicine, Benghazi University, Benghazi, Libya.
[7]
Abdelbaset Buhmeida , Center of Excellence in Genomic Medicine Research (CEGMR) King Abdul-Aziz University, Jeddah, Saudi Arabia.
[8]
D. S. Sheriff , Department of Biochemistry, Faculty of Medicine, Benghazi University, Benghazi, Libya.
[9]
Adam Elzagheid , Department of Pathology, Faculty of Medicine, Benghazi University, Benghazi, Libya; Biotechnology Research Center, Twisha, Tripoli.
Aim: The present study is undertaken to evaluate E-cadherin expression in a series of Libyan colorectal cancer cases to get an insight in its potential prognostic value in colorectal cancer in Libyan patients. Materials and Methods: A series of 81 Libyan patients with colorectal carcinoma were retrospectively studied. All carcinomas were selected from the archives of the Department of pathology, Benghazi University, derived from the period from January 2007 to December 2011. All tumors were classified using the histopathological criteria of the World Health Organization (WHO) classification, and staging was made according to the criteria of tumor-node-metastasis (TNM) classification of the International Union against Cancer. Results and Discussion: Immuno Histo chemical (IHC) analysis was done using the automatic system (BenchMark XT, Ventana Medical System, Inc. Tucson, Arizona, USA). This fully automated processing of code-labeled slides included baking of the slides, solvent free deparaffinization, antigen retrieval in a cell conditioning buffer CCI (Mild: 36 minutes conditioning, and standard: Two staining indexes were calculated: the membrane index (MI) and cytoplasmic index (CI). These indices were calculated with both the intensity of staining and the fraction of positively-stained cells taken into account using the following formula: I= 0 x f0 + 1 x f1 + 2 x f2 + 3 x f3 Our data showed that loss of E-cadherin expression is more frequently detected in older age group and in colorectal cancer patients with lymph node involvement; 75% of tumors with lymph node involvement showed negative expression of E-cadherin. One of the most important finding of the current study is the association of E-cadherin expression with the disease outcome. Conclusion: These data suggest that the loss of the E-cadherin function could be associated with invasiveness, lymph node metastasis and distant metastasis resulting in poor prognosis.
Cadherin, Colorectal Carcinoma, Immunohistochemistry
[1]
Gingras D, Béliveau R. Colorectal cancer prevention through dietary and lifestyle modifications. Cancer Microenviron. 2011;4(2):133-9.
[2]
Karsa LV, Lignini TA, Patnick J, Lambert R, Sauvaget C. The dimensions of the CRC problem. Best Pract Res Clin Gastroenterol. 2010;24(4):381-96.
[3]
Ross JS, Torres-Mora J, Wagle N, Jennings TA, Jones DM. Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol 2010;134:478–90.
[4]
Cappellani A, Di Vita M, Zanghi A, Veroux P, Cavallaro A, Lo Menzo E, et al. Biological and clinical markers in colorectal cancer: state of the art. Front Biosci (Schol Ed) 2010;2:422–31.
[5]
Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004; 10:8229-34.
[6]
Herszenyi L, Farinati F, Cardin R, Istvan G, Molnar LD, Hritz I, et al. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 2008;8:194.
[7]
Kim HJ, Yu MH, Kim H, Byun J, Lee C. Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep 2008;41:685-92.
[8]
TakeichiM.Cadherin cell adhesion receptors as a morphogeneticregulator. Science 1991; 251: 1451-1455.
[9]
Berx G, Van Roy . The E-cadherin/ catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 2001; 3; 289-293
[10]
Overduin M, Harvey TS, Bagby S, et al. Solution structure of the epithelial cadherin domain responsible for selective cell adhesion. Science 1995; 267: 386-389.
[11]
Stanczak A, Stec R, Bodnar L, Olszewski W, Cichowicz M, Kozlowski W, Szczylik C, Pietrucha T, Wieczorek M, Lamparska-Przybysz M. Prognostic significance of Wnt 1, β-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res. 2011;17(4):955-63
[12]
Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell DevBiol 2003;19:207–35.
[13]
Van Aken E, De Wever O, Correia da Rocha AS, Mareel M. Defective E-cadherin ⁄ catenin complexes in human cancer. Virchows Arch 2001; 439:725–51.
[14]
Bondi J, Bukholm G, Nesland JM, Bakka A, Bukholm IR. An increase in the number of adhesion proteins with altered expression is associated with an increased risk of cancer death for colon carcinoma patients. Int J Colorectal Dis 2006; 21:231–7.
[15]
Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Löchner D, Birchmeier W :E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cell. J Cell Bio- 1991;113(1):173-85
[16]
Weidner N, Cote RJ, Suster S, Weiss LM. Modern surgical pathology, Saunders Elsevier, Second Edition, 2009.
[17]
Lipponen P, Collan Y. Simple quantition of immune-histochemical staining positivity in microscopy. Acta stereol 1992; 11: 125-132.
[18]
Buhmeida A, Elzagheid A, Algars A, Collan Y, Syrjänen K, Pyrhönen S. Expression of the cell-cell adhesion molecule beta-catenin in colorectal carcinomas and their metastases. APMIS. 2008; 116(1):1-9.
[19]
Elzagheid A, Algars A, Bendardaf R, Lamlum H, Ristamaki R, Collan Y, Syrjanen K, Pyrhonen S. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World J Gastroenterol. 2006;12(27):4304-9.
[20]
Ozgüven BY, Karaçetin D, Kabukçuoğlu F, Taşkin T, Yener Ş. Immunohistochemical study of E-cadherin and β-catenin expression in colorectal carcinomas. Pol J Pathol. 2011;62(1):19-24.
[21]
Fang QX, Lü LZ, Yang B, Zhao ZS, Wu Y, Zheng XC. L1, β-catenin, and E-cadherin expression in patients with colorectal cancer: correlation with clinicopathologic features and its prognostic significance. J Surg Oncol. 2010;102(5):433-42.
[22]
Miladi-Abdennadher I, Abdelmaksoud-Dammak R, Ayed-Guerfali DB, Ayadi L, Khabir A, Amouri A, Frikha F, Tahri N, Ellouz S, Frikha M, Sellami-Boudawara T,Mokdad-Gargouri R. Expression of COX-2 and E-cadherin in Tunisian patients with colorectal adenocarcinoma. Acta Histochem. 2012;114(6):577-81.
[23]
Aamodt R, Bondi J, Andersen SN, Bakka A, Bukholm G, Bukholm IR.The Prognostic Impact of Protein Expression of E-Cadherin-Catenin Complexes Differs between Rectal and ColonCarcinoma. Gastroenterol Res Pract. 2010; pii: 616023.
[24]
Karatzas G, Karayiannakis AJ, Syrigos KN, Chatzigianni E, Papanikolaou S, et al: E-cadherin expression correlates with tumor differentiation in colorectal cancer. Hepatogastroenterology 1999; 46: 232-235.
[25]
Stefanou D, Goussia AC, Arkoumani E and Agnantis NJ: Expression of vascular endothelial growth factor and the adhesion molecule E-cadherin in non-small cell lung cancer. Anticancer Res 2003; 23: 4715-4720.
[26]
Bendardaf R, Elzagheid A, Lamlum H, Ristamaki R, Collan Y, Pyrhonen S. E-cadherin, CD44s and CD44v6 correlate with tumour differentiation in colorectal cancer. Oncol Rep 2005; 13: 831-835.
[27]
Hsieh JS, Lin SR, Chang MY, Chen FM, Lu CY, Huang TJ, et al. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg 2005;71:336–43.
[28]
Wang JY, Hsieh JS, Lu CY, Yu FJ, Wu JY, Chen FM, et al. The differentially mutational spectra of the APC, K-ras, and p53 genes in sporadic colorectal cancers from Taiwanese patients. Hepatogastroenterology 2007; 54: 2259–65.
[29]
Ilyas M, Tomlinson IP, Hanby A, Talbot IC and Bodmer WFT: Allele loss, replication errors and loss of expression of E-cadherin in colorectal cancers. Gut 1997; 40: 654-659.
[30]
Wheeler JM, Kim HC, Efstathiou JA, Ilyas M, Mortensen NJ and Bodmer WF: Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut 2001; 48: 367-371.
[31]
Machado JC, Soares P, Carneiro F, Rocha A, Beck S, Blin N, Berx G and Sobrinho-Simoes M: E-Cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 1999; 79: 459-465.
[32]
Berx G, Cleton-Jansen AM, Strumane K, De Leeuw WJ, Nollet F, Van Roy F and Cornelisse CT: E-Cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996; 13: 1919-1925.
[33]
Efstathiou JA, Liu D, Wheeler JM, Kim HC, Beck NE, Ilyas M, Karayiannakis AJ, Mortensen NJ, Kmiot W, Playford RJ, Pignatelli M and Bodmer WFT: Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci USA 1999; 96: 2316-2321.
[34]
Garinis GA, Menounos PG, Spanakis NE, Papadopoulos K, Karavitis G, Parassi I, Christeli E, Patrinos GP, Manolis EN and Peros G: Hypermethylation-associated transcriptional silencing of E-cadherin in primary sporadic colorectal carcinomas. J Pathol 2002; 198: 442-449.
[35]
Ngan CY, Yamamoto H, Seshimo I, Ezumi K, Terayama M, Hemmi H, Takemasa I, Ikeda M, Sekimoto M, Monden M. A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J Surg Oncol. 2007; 95(8):652-62.
[36]
Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrjanen K. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J Pathol 1994; 174: 101-109.
[37]
Strumane K, Berx G, van Roy F. Cadherins in cancer. In: Behrens J, Nelson J, editors. Hand-book of Experimental Pharmacology. Heidelberg: Springer-Verlag, 2004; 69-103.
[38]
Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer 2003; 2: 14.
[39]
Tamura G, Yin J, Wang S, et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000; 92: 569-573.
[40]
Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res. 2008;28(6A):3815-26.
